%0 Journal Article
%T Triple Effect of Doxorubicin, 5-Fluorouracil, Propranolol on Cell Survival on MCF-7 Breast Cancer Cell Line
%A Onur Eroglu
%A Hacer Kaya
%A Esin Guvenir Celik
%A Merve Celen
%A Elif Korkut
%A Nagihan Nizam
%J Journal of Biosciences and Medicines
%P 74-85
%@ 2327-509X
%D 2019
%I Scientific Research Publishing
%R 10.4236/jbm.2019.72007
%X <b>Purpose: </b>Investigating the
triple effect of doxorubicin, 5-fluorouracil, propranolol on MCF-7 (ER+, WTp53)
breast cancer cell line with MTT test and survival analysis. <b>Materials/Methods:</b> In order to determine effective dosages of a combination of doxorubicin,
5-fluorouracil, propranolol on the MCF-7 cell line by using MTT and survival
analysis technique. <b>Result:</b> IC<sub>50</sub> values acquired by MTT tests
are 0.01 mg/ml for doxorubicin, 6 mg/ml for 5-fluorouracil, 30 mg/ml for
propranolol and 0.2/1/30 mg/ml (with previous respect) if all three agents are
combined. It is found that the use of doxorubicin, 5-fluorouracil, and
propranolol in combination is much effective than their single application. <b>Discussion:</b> Moderate concentrations of doxorubicin, 5-fluorouracil, and propranolol, if they
are applied individually, showed high toxicity. When we used these drugs in
combination; toxic effects lessened with respect to monotherapy. In the MCF-7
cell line, doxorubicin (IC<sub>50</sub>: 0.01 ¦ÌM) increases cell death rates
significantly and propranolol (IC<sub>50</sub>: 3 ¦ÌM) has minimum effects in
monotherapy in contrast to others. Propranolol is only superior to itself in
combination therapy (IC<sub>50</sub>: 4 ¦ÌM). However 5-fluorouracil
(IC<sub>50</sub>: 30 ¦ÌM) showed antagonistic effects with respect to other
drugs. Additionally, having applied the three drugs in combination on the MCF-7
cell line for the first time in literature, it is highly possible to assess the
application of doxorubicin, 5-fluorouracil and propranolol combination as a
novel therapy option.
%K MCF-7
%K Breast Cancer
%K Combine Treatment
%K Doxorubicin
%K 5-Fluorouracil
%K Propranolol
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=90494